NetworkNewsBreaks – Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) Featured in Mizuho Securities Research Report
Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Satsuma reported better-than expected 4Q19 EPS loss of ($0.62) vs our ($0.79), driven by lower OpEx of $11M vs our $15M. However, we believe earnings numbers are not meaningful at this stage of its development. We continue to like STSA, believing STS101 remains underappreciated, and we like its strong cash position exiting 2019 that should take it to the end of 2021, which should shield it from needing to find additional funding in a potentially worsening capital markets…







